{"id":814142,"date":"2025-02-18T08:53:38","date_gmt":"2025-02-18T13:53:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/"},"modified":"2025-02-18T08:53:38","modified_gmt":"2025-02-18T13:53:38","slug":"silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/","title":{"rendered":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong><br \/>\n          <em>SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>SARASOTA, FL, Feb.  18, 2025  (GLOBE NEWSWIRE) &#8212;  Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. <\/p>\n<p>Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University.<\/p>\n<p>The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8q-SAHUAyAbnF5FZrNJDt3STwQvt63Ws5NLLtUCFwYDJcq0sk4XLuQd_YB9QalSLi40C2skYWyD92gIIyF7I1RKf8flNRQd3y5DgQV4UHE9cKwSGueWFeiNmQlf0LrxArX8K_diTdnN1soCKjJTcx8PxZ9uxpribf2XMZqr_7DqsVcRVCLRS7kOzTEHJF_oHhel6VW18cCAQCkHMwhWEqcAMutA3w8VeQRAKhklviFAFEfKMA9OAMLbx4JL9lkGj3exepyI9C5LTdNQOgJNqFnXqKc00K_NI5Bh2wsO8jV4=\" rel=\"nofollow\" target=\"_blank\">preclinical study<\/a> of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, combined with an N-methyl-D-aspartate receptor (NMDAR) antagonist demonstrated significant improvement in behavioral outcomes and a marked reduction in severe stress-induced conditions.<\/p>\n<p>\u201cWe believe that the SPC-15 combination treatment is showing promise in multiple stress-induced behaviors and disorders. This provisional patent application, if approved and the patent issued, will augment and expand the existing patents on this technology which we originally acquired through our global license agreement,\u201d said Eric Weisblum, CEO of Silo. <\/p>\n<p>Silo recently filed a separate expanded provisional patent application covering the chronic, combinatorial targeting of NMDARs and 5-HT4Rs to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia.\u00a0<\/p>\n<p>\n        <strong>About SPC-15<\/strong><\/p>\n<p>SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA\u2019s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.<\/p>\n<p>\n        <strong>About Silo Pharma<\/strong><\/p>\n<p>Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease and multiple sclerosis. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fCIaNyhiUee97fA6Vul-K2r2__JZWWGk_sg_c5ip2SXiHfjlRPftTCnYtcPYj5JQlWQ-1TiLyny0qeHeQAaBkQACHC7-_Twr1IaxWNwDRIkCcMkvwZ_O8E2Vqwtx7DbhQp9tjbLGsI5Vgj1NiI6gRdRq3hDTEo1LbIvvJsINFp1wbOa2vqyW69WKyg3BKpgOi3wy70nQSA9Rk66z-f9Wm3WStUSXmK6XcJz0mxTBYmg=\" rel=\"nofollow\" target=\"_blank\">silopharma.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><\/p>\n<p>This news release contains &#8220;forward-looking statements&#8221; within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p>\n        <strong>Contact<\/strong><\/p>\n<p>800-705-0120<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0QLIHRxj9ZWZezsQXES7tla86b8_f9it0pbM7wYitTrBij-Cmg6yJr7-QpmjXBB2aJSwgXWklsDgLfSKSZ70BlwjmqD2t8_uauIp8xiK5fwR7dBlSvzew0ybrrhQsc5jw6O9ng5oSnfNxyz5GSIw9PKpR9ZuDewhuzBAWvfYFuoEhCl73Le_Jy07kDUZLbVWhYEKwOIPm4LkVPk-Z0XB734pjXci24BFQIiiipqefIJ9HwNDwDtpHgEWOApHjMuNhceeu2qEWc9_FsHsSSNgA1oPFshGMDqYv_ei98gIRkA06mV3TVhyDUUrwFLawC2IrJdd0StvDHpDA6ULlbSwY_V_NzWZLkU7bmZwRJl15PV2SZpFsXA1pe51SbRPlNt2czeHcIAGL1DkNWWl71fL5pKLrnuHp3mYloUkqZ0voQVSA2_PbhShJeBgf8NkyPe4QXbbc07atBzQQbz1crQMDlMJTDxJGGTtnxqAT_KgSdZy4DqYZl9tTDz1L2We9cnMEp9q16LbNSCtHXMDT05k3XrVu_efJ37HMJdYub-hx5nhIv2Nbr0pdP2EsXwhlhnQF4fVxex9cgVaSrkH7Swk3afud6ySHlQZHXztt41T1kXWrs3eG_C_wnxYyOhRY-HKBXfL6odaMvUwQdrcgnhYEpQF5FvSa4xlU4m2MGsggoU383s80qqaOu8Bty_lb8pB4PM084z2wt6ld_wcSr0QiFj9KIxq34KXrh5EI7Ced_ruJrIiiNkZx-_0MWYAnJQ_2lP6ojvGUwXVvODqA4ozXUl4m3RkW5qkiM4HxygsNzw=\" rel=\"nofollow\" target=\"_blank\">investors@silopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGMwYzExNGYtZGIyNi00NDFlLWExZTItNmE4OGE4NDE2ZGMxLTUwMDA2OTMzOQ==\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814142","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) &hellip; Continue reading &quot;Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T13:53:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment\",\"datePublished\":\"2025-02-18T13:53:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/\"},\"wordCount\":589,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/\",\"name\":\"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\",\"datePublished\":\"2025-02-18T13:53:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk","og_description":"SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) &hellip; Continue reading \"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-18T13:53:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment","datePublished":"2025-02-18T13:53:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/"},"wordCount":589,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/","name":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==","datePublished":"2025-02-18T13:53:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDA2OSM2NzU1Njk2IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent-filing-for-innovative-spc-15-combination-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814142"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814142\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}